Literature DB >> 10882273

Equilibrium-phase MR angiography of the aortoiliac and renal arteries using a blood pool contrast agent.

D Weishaupt1, S G Rühm, C A Binkert, M Schmidt, M A Patak, F Steybe, S McGill, J F Debatin.   

Abstract

OBJECTIVE: The purpose of this study was to determine the diagnostic usefulness of a new blood pool contrast agent, NC100150, for assessing the aortoiliac and renal arteries. SUBJECTS AND METHODS: Twenty patients with hemodynamically significant stenosis (> or =50% of luminal diameter) of the iliac or renal arteries or an aortic aneurysm documented by digital subtraction angiography underwent MR angiography at 1.5 T after administration of NC100150. Three-dimensional MR angiographic data sets were collected ill the equilibrium phase. In a prospective analysis, each vascular segment (16 segments per arterial tree) was evaluated.
RESULTS: All patients tolerated the NC100150 administration well. Mean contrast-to-noise ratios of the vascular data collected in the equilibrium phase of NC100150 was 3.3+/-15.9. Compared with digital subtraction angiography, the sensitivity and specificity of MR angiography for the renal arteries were 82% and 98%, respectively; for the common iliac arteries, 86% and 97%, respectively; for the external iliac arteries, 80% and 100%, respectively; and for the internal iliac arteries, 71% and 977, respectively. All 83 aneurysmal changes revealed by digital subtraction angiograpy of the aortoiliac arteries were well displayed on the MR angiographic data sets.
CONCLUSION: Equilibrium-phase NC 00150-enhanced three-dimensional MR angiography shows high specificity when evaluating the abdominal and pelvic vascular systems, but the attendant venous overlap can limit the assessment of stenosis in renal and pelvic arterial segments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882273     DOI: 10.2214/ajr.175.1.1750189

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography.

Authors:  Tim Leiner; Kai Yiu J A M Ho; Vincent B Ho; Georg Bongartz; Willem P T M Mali; Wenche Rasch; Jos M A van Engelshoven
Journal:  Eur Radiol       Date:  2003-01-18       Impact factor: 5.315

2.  Pre-clinical results with Clariscan (NC100150 Injection); experience from different disease models.

Authors:  A Bjørnerud; L O Johansson; H K Ahlström
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.310

3.  Contrast-enhanced MR Angiography without Gadolinium-based Contrast Material: Clinical Applications Using Ferumoxytol.

Authors:  Mohammad H Jalili; Tiffany Yu; Cameron Hassani; Ashley E Prosper; J Paul Finn; Arash Bedayat
Journal:  Radiol Cardiothorac Imaging       Date:  2022-08-04

Review 4.  A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics.

Authors:  Pedro Farinha; João M P Coelho; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Nanomaterials (Basel)       Date:  2021-12-17       Impact factor: 5.076

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.